MSME (Udyam registered) Ministry of MSME
- Udyam number
- UDYAM-DL-08-0006704
Irx Pharmaceuticals Private Limited - pharma in New Delhi, Delhi, India. FY 2026 financials & compliance.
Revenue · FY 2026
₹24.58 Cr
▲ 109% YoY
Net profit · FY 2026
₹8.3 Cr
Net margin 33.8%
EBITDA · FY 2026
₹11.11 Cr
EBITDA margin 45.2%
Authorised capital
₹1 Lakh
Registered with MCA
Paid-up capital
₹98,060
Issued & subscribed
Company age
6 yrs
Est. 2020
Employees · EPFO
10
Provident fund records
Directors on board
5
As per MCA filings
About Irx Pharmaceuticals Private Limited
Data last updated:
Irx Pharmaceuticals Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 14 October 2020 and has been in existence for over 6 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24110DL2020PTC371543. Its GSTIN is 07AAFCI8531G1ZJ (Delhi).
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹98,060. It is led by directors including Mahipal Singh Sachdev and Ritika Sachdev Gupta.
Its last annual general meeting (AGM) was held on 10 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at B – 5/24 Safdarjung Enclave, New Delhi, Delhi, India – 110029.
As per the financials filed for FY 2026, the company reported a revenue of ₹24.58 Cr, a growth of 109% compared to the previous year. For the same year it recorded a net profit of ₹8.3 Cr (net margin 33.8%) and EBITDA of ₹11.11 Cr (EBITDA margin 45.2%). Revenue has grown at a compounded annual rate (CAGR) of 53% over three years.
The company has about 10 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Centre for Sight.
Irx Pharmaceuticals Private Limited is registered as an MSME under the Udyam registration framework (Reg. No. UDYAM-DL-08-0006704). For more details, the company can be reached via its website irxpharmaceuticals.com.
Company details
CIN U24110DL2020PTC371543
Registration Number 371543
Incorporation Date 14 October 2020
ROC Delhi
Listing Status Unlisted
Company Status Active
MSME Classification MSME
Udyam Registration UDYAM-DL-08-0006704
Recognitions & Rankings of Irx Pharmaceuticals
Contact details
Irx Pharmaceuticals Private Limited's registered office is in New Delhi, Delhi. Its website is irxpharmaceuticals.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressB – 5/24 Safdarjung Enclave, New Delhi, Delhi, India – 110029
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Irx Pharmaceuticals Private Limited, buy the company report.
Comprehensive company report
Irx Pharmaceuticals Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Irx Pharmaceuticals operates one associated brand: Centre for Sight. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Chain of eye care hospitals | centreforsight.net |
Business activity
The main business activity of Irx Pharmaceuticals is human health and social work activities. In detail, this covers human health activities.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| Q | Human health and social work activities | 86 | Human health activities |
To see the full business activity and turnover split of Irx Pharmaceuticals Private Limited, buy the company report.
Financials of Irx Pharmaceuticals Private Limited
FY 2026 filings availableIrx Pharmaceuticals Private Limited reported revenue of ₹24.58 Cr (up 109% YoY) for FY 2026.
Revenue · FY 2026
₹24.58 Cr ▲ 109%
Net profit · FY 2026
₹8.3 Cr margin 33.8%
EBITDA · FY 2026
₹11.11 Cr margin 45.2%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 109%
3 years · compounded
▲ 53%
EBITDA CAGR growth
1 year
▲ 68%
3 years · compounded
▲ 36%
Revenue has grown at a compounded annual rate (CAGR) of 53% over three years, including 109% growth in the latest year. EBITDA rose 68% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | ₹24.58 Cr | ||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹11.11 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹8.3 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 45.2% | ||||
| Net Profit Margin | 33.8% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Irx Pharmaceuticals Private Limited, buy the company report.
Board of directors of Irx Pharmaceuticals Private Limited
Irx Pharmaceuticals has 5 directors on record. No former directors are listed.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Mahipal Singh Sachdev Also directs: Laxmi Ophthalmic Services Private Limited, Ndcfs Foundation, Vishwanethra Health Services Private Limited and 5 more | Director | 14 Oct 2020 | 6 Years 0 Months | Current |
| Ritika Sachdev Gupta Also directs: Laxmi Ophthalmic Services Private Limited, Ndcfs Foundation, Vishwanethra Health Services Private Limited and 5 more | Director | 14 Oct 2020 | 6 Years 0 Months | Current |
| Alka Sachdev Also directs: Ndcfs Foundation, Vishwanethra Health Services Private Limited, Shri Divyadrashti Laser Clinic Private Limited and 5 more | Director | 28 Feb 2025 | 1 Years 8 Months | Current |
| Ajay Jassal | Director | 28 Feb 2025 | 1 Years 8 Months | Current |
| Shankar Narang Also directs: New Delhi Centre for Sight Limited, Challa Eye Care Private Limited, Mehta Eye Clinic Private Limited and 3 more | Director | 28 Feb 2025 | 1 Years 8 Months | Current |
Auditor
Irx Pharmaceuticals Private Limited is audited by K P V & CO for the financial year 2026.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| K P V & CO | FY 2026 | 042332N |
Shareholding
The shareholding of Irx Pharmaceuticals Private Limited is on record for 5 financial years, the latest being FY 2026, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Irx Pharmaceuticals Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Irx Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Irx Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Irx Pharmaceuticals Private Limited has a workforce of 10 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.
Employee count
10
Active EPFO establishments
1
Employee growth
233.3%
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 10 |
| FY 2025-26 |
To see the full employee and EPFO history of Irx Pharmaceuticals Private Limited, buy the company report.
GST
Irx Pharmaceuticals has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AAFCI8531G1ZJ | Delhi | Active | 13 Dec 2020 |
To see the full GST registrations and return filing status of Irx Pharmaceuticals Private Limited, buy the company report.
Recent activity
Irx Pharmaceuticals Private Limited has 5 board changes on record since 2020: 5 appointments. The latest: Ajay Jassal was appointed as Director on 28 Feb 2025.
Filing
Irx Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Delhi.
AGM
Irx Pharmaceuticals Private Limited last Annual general meeting of members was held on 10 Sep 2025 as per latest MCA records.
Appointed
Ajay Jassal was appointed as Director.
Appointed
Alka Sachdev was appointed as Director.
Appointed
Shankar Narang was appointed as Director.
Appointed
Mahipal Singh Sachdev was appointed as Director.
Appointed
Ritika Sachdev Gupta was appointed as Director.
Incorporation
14 Oct 2020
Irx Pharmaceuticals Private Limited was registered on 14 Oct 2020 with Roc Delhi & aged 6 years 30 days as per MCA records.
Frequently asked questions
Irx Pharmaceuticals is an active private limited company based in New Delhi, Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 14 October 2020 (6+ years old) and is registered under CIN U24110DL2020PTC371543.
Irx Pharmaceuticals has 5 current directors:
- Mahipal Singh Sachdev - Director
- Ritika Sachdev Gupta - Director
- Alka Sachdev - Director
- Ajay Jassal - Director
- Shankar Narang - Director
The latest financial statements of Irx Pharmaceuticals on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 10 September 2025. Year-wise statements from FY 2021 are in the company report.
The GSTIN of Irx Pharmaceuticals is 07AAFCI8531G1ZJ, registered in Delhi.
The CIN (Corporate Identification Number) of Irx Pharmaceuticals is U24110DL2020PTC371543. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Irx Pharmaceuticals was incorporated on 14 October 2020, making it 6+ years old. It is registered with the Registrar of Companies, Delhi.
Ajay Jassal was appointed as Director on 28 Feb 2025. Alka Sachdev was appointed as Director on 28 Feb 2025. Shankar Narang was appointed as Director on 28 Feb 2025. Irx Pharmaceuticals has 5 board changes on record in total.
Yes, Irx Pharmaceuticals is registered as an MSME under Udyam registration (number: UDYAM-DL-08-0006704).
Irx Pharmaceuticals can be reached through the website irxpharmaceuticals.com. Its registered office is in New Delhi, Delhi, India.
The registered office of Irx Pharmaceuticals is at B – 524 Safdarjung Enclave, New Delhi, Delhi, India – 110029.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages